Lotus Orionin Stalevo®- ja Comtan®-lääkkeiden jakelijaksi osassa Aasiaa
30 déc. 2019 02h00 HE
|
Orion Oyj
ORION OYJ LEHDISTÖTIEDOTE 30.12.2019 klo 09.00 Orion Oyj (”Orion”) ja Lotus Pharmaceutical Co., Ltd. (”Lotus”) ovat tehneet markkinointi- ja jakelusopimuksen koskien Orionin...
Lotus to distribute Orion’s Stalevo® and Comtan® drugs in parts of Asia
30 déc. 2019 02h00 HE
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 30 DECEMBER 2019 at 9.00 EET Orion Corporation (“Orion”) and Lotus Pharmaceutical Co., Ltd. (“Lotus”) have made a marketing and distribution...
Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference
12 déc. 2019 07h07 HE
|
Aptinyx Inc.
EVANSTON, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson’s Disease
05 déc. 2019 06h58 HE
|
Aptinyx Inc.
Phase 2 study follows NYX-458 preclinical data demonstrating reversal of cognitive deficits in non-human primate model of Parkinson’s disease Fourth Phase 2 study initiated by Aptinyx in 2019 across...
Herantis Pharma Oyj:n suunnattu osakeanti on ylimerkitty moninkertaisesti ja toteutetaan suunnitellusti
02 déc. 2019 13h00 HE
|
Herantis Pharma Oyj
Herantis Pharma Oyj:n suunnattu osakeanti on ylimerkitty moninkertaisesti ja toteutetaan suunnitellusti Herantis Pharma Oyj Yhtiötiedote 2.12.2019 kello 20:00 TÄMÄN TIEDOTTEEN SISÄLTÄMÄ TIETO EI...
Herantis Pharma Plc's directed share issue is oversubscribed multiple times and completed as planned
02 déc. 2019 13h00 HE
|
Herantis Pharma Oyj
Herantis Pharma Plc's directed share issue is oversubscribed multiple times and completed as planned Herantis Pharma Plc Company release 2 December 2019 at 8:00 pm THE INFORMATION CONTAINED IN...
Aptinyx to Present at Upcoming Investor Conferences
14 nov. 2019 07h57 HE
|
Aptinyx Inc.
EVANSTON, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Curium Announces Plan to Submit an Application to Market Generic Ioflupane I 123 Injection in the U.S.
13 nov. 2019 08h00 HE
|
Curium
St. Louis MO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Curium announced today that it intends to submit an abbreviated new drug application for a generic version of DaTscanTM (Ioflupane I 123 Injection) in...
Aptinyx Reports Third Quarter 2019 Financial Results and Highlights
12 nov. 2019 16h01 HE
|
Aptinyx Inc.
Initiated two Phase 2 studies of NYX-2925 in chronic pain conditions On track to have four Phase 2 studies ongoing by year end across pipeline of CNS product candidates Conference call today at 5:00...
Aptinyx to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
05 nov. 2019 08h07 HE
|
Aptinyx Inc.
EVANSTON, Ill., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...